Alpha 2.0
Login Register
» Articles » PMID: 3145869

Ceftibuten (7432-S, SCH 39720): Comparative Antimicrobial Activity Against 4735 Clinical Isolates, Beta-lactamase Stability and Broth Microdilution Quality Control Guidelines

Overview
Journal Eur J Clin Microbiol Infect Dis
Publisher Springer
Specialties Infectious Diseases
Microbiology
Date 1988 Dec 1
PMID 3145869
Citations 12
Authors
R N Jones
A L Barry
Affiliations
Soon will be listed here.
Abstract

The antimicrobial activity of ceftibuten, a new oral cephalosporin, was evaluated using 4735 clinical bacterial isolates processed at four medical centers. Ceftibuten inhibited nearly 92% of all Enterobacteriaceae (less than or equal to 8.0 micrograms/ml), thereby being markedly superior to cefixime which inhibited 78.7% at less than or equal to 1.0 microgram/ml and cefuroxime which inhibited 45.1% at less than or equal to 2.0 micrograms/ml. Pseudomonads and staphylococci were not within the spectrum of activity of ceftibuten. Ceftibuten was found to be very stable in the presence of five commonly occurring beta-lactamases of both the chromosomal-mediated (P99, K1) and plasmid-mediated (CARB-2, OXA-1, TEM-1) types. Only Type Ia (P99) beta-lactamase was significantly inhibited by ceftibuten. On the basis of results of a ceftibuten MIC quality control study conducted in five laboratories, a quality control range of 0.12 to 0.5 microgram/ml is recommended for the Escherichia coli ATCC 25922 strain.

Citing Articles

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes.

Trout R, Zulli A, Mesaros E, Jackson R, Boyd S, Liu B J Med Chem. 2021; 64(14):10155-10166.

PMID: 34191513 PMC: 8311649. DOI: 10.1021/acs.jmedchem.1c00437.

Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis.

ZIERING W, McElvaine P Infection. 1998; 26(1):68-75.

PMID: 9505188 DOI: 10.1007/BF02768764.

Susceptibilities of beta-lactamase-producing and -nonproducing ampicillin-resistant strains of Haemophilus influenzae to ceftibuten, cefaclor, cefuroxime, cefixime, cefotaxime, and amoxicillin-clavulanic acid.

Barry A, Fuchs P, Pfaller M Antimicrob Agents Chemother. 1993; 37(1):14-8.

PMID: 8431012 PMC: 187597. DOI: 10.1128/AAC.37.1.14.

Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use.

Kearns G, Young R Clin Pharmacokinet. 1994; 26(3):169-89.

PMID: 8194281 DOI: 10.2165/00003088-199426030-00002.

Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections.

Onyeji C, Nicolau D, Nightingale C, Quintiliani R Antimicrob Agents Chemother. 1994; 38(5):1112-7.

PMID: 8067747 PMC: 188159. DOI: 10.1128/AAC.38.5.1112.

References
1.
Barry A, Gavan T, Jones R, Ayers L, Fuchs P, Gerlach E . Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid. Diagn Microbiol Infect Dis. 1987; 7(1):83-7. DOI: 10.1016/0732-8893(87)90076-9. View
2.
Preston D, Jones R, Barry A, Thornsberry C . Comparison of the antibacterial spectra of cephalexin and cefaclor with those of cephalothin and newer cephalosporins: reevaluation of the class representative concept of susceptibility testing. J Clin Microbiol. 1983; 17(6):1156-8. PMC: 272818. DOI: 10.1128/jcm.17.6.1156-1158.1983. View
3.
Chin N, Neu H . Comparative antibacterial activity of a new oral cephalosporin, BMY-28100. Antimicrob Agents Chemother. 1987; 31(3):480-3. PMC: 174759. DOI: 10.1128/AAC.31.3.480. View
4.
Barry A, Thornsberry C, Jones R, Fuchs P, Gavan T, Gerlach E . Cefuroxime, an in vitro Comparison with Six Other Cephalosporins. Proc R Soc Med. 2010; 70(Suppl 9):63-71. PMC: 1543212. View
5.
Fuchs P, Barry A, Jones R . Cefixime disk susceptibility test criteria. J Clin Microbiol. 1986; 24(4):647-9. PMC: 268991. DOI: 10.1128/jcm.24.4.647-649.1986. View